Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial 

News

April 12, 2023
PRESS RELEASE: On April 10, 2023, a new research paper was published in Oncotarget, entitled, “A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.” continue reading »

Crosstalk Between Triple Negative Breast Cancer and Microenvironment

News

April 10, 2023
PRESS RELEASE: On March 31, 2023, researchers from Albany College published a new review in Oncotarget, entitled, “Crosstalk between triple negative breast cancer and microenvironment.” continue reading »

Cancer-Associated Fibroblasts: Challenges and Opportunities

News

April 5, 2023
PRESS RELEASE: On March 21, 2023, a new editorial perspective was published in Oncotarget, entitled, “Cancer-associated fibroblasts: challenges and opportunities.” continue reading »

Impact of Cortactin in Cancer Progression

News

April 4, 2023
PRESS RELEASE: On March 21, 2023, a new editorial paper was published in Oncotarget, entitled, “Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.” continue reading »

Targeting Pre-Leukemic Cells: New Hope for Preventing Childhood B-ALL

Oncotarget

March 31, 2023
Researchers from Universidad Autónoma de Madrid published a new editorial in Oncotarget detailing a proof-of-principle experiment to prevent B-cell acute lymphoblastic leukemia (B-ALL). continue reading »